S&P 500 6,976.44 ▲ 37.41 (+0.54%)
DOW 49,407.66 ▲ 515.19 (+1.05%)
NASDAQ 23,592.11 ▲ 130.29 (+0.56%)
US Markets Closed

ALKS

Alkermes plc

Price Chart
Latest Quote

$34.96

Current Price
Previous Close $33.89
Open $33.54
Day High $35.30
Day Low $33.46
Volume 1,786,712
Fetched: 2026-02-02T22:52:30
Stock Information
Shares Outstanding 165.12M
Total Debt $71.60M
Cash Equivalents $1.11B
Revenue $1.52B
Net Income $338.06M
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Market Cap $5.77B
P/E Ratio 17.39
EPS (TTM) $2.01
Exchange NMS
🌐 Visit Website
📊 Custom Metrics & Score
Score: 29/42
Debt to Equity 0.05
Debt to Earnings 0.06
Current Ratio 3.04
Quick Ratio 2.45
Avg Revenue Growth 8.18%
Profit Margin 23.57%
Return on Equity 25.06%
Avg FCF Growth 114.50%
FCF Yield 7.03%
Score Explanation: The perfect score is 42/42 based on debt levels, profitability, growth rates, and cash flow metrics. FCF Yield is weighted most heavily as it shows what return the business currently generates.
Recent Price History
Date Close Volume
2026-02-02 $34.96 1,786,712
2026-01-30 $33.89 2,388,400
2026-01-29 $34.88 2,817,300
2026-01-28 $33.90 1,727,800
2026-01-27 $33.52 1,557,700
2026-01-26 $33.11 2,462,300
2026-01-23 $33.61 3,010,200
2026-01-22 $33.95 2,755,500
2026-01-21 $33.85 3,269,200
2026-01-20 $31.75 2,167,000
2026-01-16 $31.63 2,418,300
2026-01-15 $31.22 2,897,300
2026-01-14 $30.62 1,860,800
2026-01-13 $29.15 2,082,300
2026-01-12 $29.62 1,675,500
2026-01-09 $29.66 2,820,800
2026-01-08 $29.60 2,311,400
2026-01-07 $29.36 2,299,600
2026-01-06 $28.78 2,033,000
2026-01-05 $28.00 1,627,000
About Alkermes plc

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

Income Statement (Annual)
Revenue
Metric 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Reconciled Cost Of Revenue $217,899,000 $213,799,000 $176,569,000 $156,819,000
Cost Of Revenue $245,331,000 $253,037,000 $218,068,000 $197,323,000
Total Revenue $1,557,632,000 $1,663,405,000 $1,111,795,000 $1,173,751,000
Operating Revenue $1,557,632,000 $1,663,405,000 $1,111,795,000 $1,173,751,000
Expenses
Metric 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Interest Expense $22,578,000 $23,032,000 $13,040,000 $11,219,000
Total Expenses $1,136,996,000 $1,249,283,000 $1,117,884,000 $1,076,005,000
Other Income Expense $3,242,000 $-425,000 $-19,628,000 $-1,208,000
Other Non Operating Income Expenses $3,242,000 $-425,000 $2,122,000 $219,000
Net Non Operating Interest Income Expense $19,872,000 $7,822,000 $-5,411,000 $-8,811,000
Interest Expense Non Operating $22,578,000 $23,032,000 $13,040,000 $11,219,000
Operating Expense $891,665,000 $996,246,000 $899,816,000 $878,682,000
Selling And Marketing Expense $446,214,000 $490,154,000 $392,211,000 -
General And Administrative Expense $199,024,000 $199,597,000 $198,540,000 -
Income & Earnings
Metric 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Net Income From Continuing Operation Net Minority Interest $372,138,000 $519,157,000 $-33,152,000 $76,401,000
Net Interest Income $19,872,000 $7,822,000 $-5,411,000 $-8,811,000
Interest Income $42,450,000 $30,854,000 $7,629,000 $2,408,000
Normalized Income $372,138,000 $519,157,000 $-15,969,500 $77,643,917
Net Income From Continuing And Discontinued Operation $367,070,000 $355,757,000 $-158,267,000 $-48,169,000
Total Operating Income As Reported $420,636,000 $414,122,000 $-6,089,000 $97,746,000
Net Income Common Stockholders $367,070,000 $355,757,000 $-158,267,000 $-48,169,000
Net Income $367,070,000 $355,757,000 $-158,267,000 $-48,169,000
Net Income Including Noncontrolling Interests $367,070,000 $355,757,000 $-158,267,000 $-48,169,000
Net Income Discontinuous Operations $-5,068,000 $-163,400,000 $-125,115,000 $-124,570,000
Net Income Continuous Operations $372,138,000 $519,157,000 $-33,152,000 $76,401,000
Pretax Income $443,750,000 $421,519,000 $-31,128,000 $87,727,000
Special Income Charges $0 $0 $-21,750,000 $-1,427,000
Interest Income Non Operating $42,450,000 $30,854,000 $7,629,000 $2,408,000
Operating Income $420,636,000 $414,122,000 $-6,089,000 $97,746,000
Depreciation Amortization Depletion Income Statement $1,101,000 $35,689,000 $36,363,000 $38,148,000
Depreciation And Amortization In Income Statement $1,101,000 $35,689,000 $36,363,000 $38,148,000
Amortization Of Intangibles Income Statement $1,101,000 $35,689,000 $36,363,000 $38,148,000
Gross Profit $1,312,301,000 $1,410,368,000 $893,727,000 $976,428,000
Per Share Metrics
Metric 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Diluted EPS $2.17 $2.10 $-0.97 $-0.30
Basic EPS $2.22 $2.14 $-0.97 $-0.30
Other
Metric 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Tax Effect Of Unusual Items $0 $0 $-4,567,500 $-184,083
Tax Rate For Calcs $0 $0 $0 $0
Normalized EBITDA (Bullshit earnings) $494,861,000 $519,478,000 $81,524,000 $179,025,000
Total Unusual Items $0 $0 $-21,750,000 $-1,427,000
Total Unusual Items Excluding Goodwill $0 $0 $-21,750,000 $-1,427,000
Reconciled Depreciation $28,533,000 $74,927,000 $77,862,000 $78,652,000
EBITDA (Bullshit earnings) $494,861,000 $519,478,000 $59,774,000 $177,598,000
EBIT $466,328,000 $444,551,000 $-18,088,000 $98,946,000
Diluted Average Shares $169,198,000 $169,730,000 $163,742,000 $160,942,000
Basic Average Shares $165,392,000 $166,223,000 $163,742,000 $160,942,000
Diluted NI Availto Com Stockholders $367,070,000 $355,757,000 $-158,267,000 $-48,169,000
Tax Provision $71,612,000 $-97,638,000 $2,024,000 $11,326,000
Restructuring And Mergern Acquisition $0 $0 $21,750,000 $1,427,000
Amortization $1,101,000 $35,689,000 $36,363,000 $38,148,000
Research And Development $245,326,000 $270,806,000 $272,702,000 $290,924,000
Selling General And Administration $645,238,000 $689,751,000 $590,751,000 $549,610,000
Other Gand A $199,024,000 $199,597,000 $198,540,000 -
Fetched: 2026-02-02
Balance Sheet (Annual)
Assets
Metric 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Net Tangible Assets $1,381,060,000 $1,117,668,000 $923,046,000 $945,668,000
Total Assets $2,055,567,000 $2,136,223,000 $1,963,978,000 $2,024,484,000
Total Non Current Assets $640,212,000 $650,717,000 $833,672,000 $962,315,000
Other Non Current Assets $16,503,000 $11,521,000 $146,325,000 $27,455,000
Non Current Deferred Assets $154,835,000 $195,888,000 $114,572,000 $81,833,000
Non Current Deferred Taxes Assets $154,835,000 $195,888,000 $114,572,000 $81,833,000
Investmentin Financial Assets $73,148,000 $39,887,000 $131,610,000 $229,430,000
Goodwill And Other Intangible Assets $83,917,000 $85,018,000 $120,707,000 $166,916,000
Other Intangible Assets $890,000 $1,991,000 $37,680,000 $74,043,000
Current Assets $1,415,355,000 $1,485,506,000 $1,130,306,000 $1,062,169,000
Other Current Assets $91,282,000 $98,166,000 $41,203,000 $48,967,000
Assets Held For Sale Current $0 $94,260,000 $2,324,000 -
Inventory $182,887,000 $186,406,000 $181,418,000 $150,335,000
Receivables $389,518,000 $333,183,000 $296,896,000 $326,556,000
Receivables Adjustments Allowances $-300,000 $-200,000 $-200,000 -
Other Receivables $74,490,000 $103,806,000 $80,929,000 $13,363,000
Accounts Receivable $315,328,000 $229,577,000 $216,167,000 $313,193,000
Gross Accounts Receivable $315,328,000 $229,577,000 $216,167,000 $313,393,000
Cash Cash Equivalents And Short Term Investments $751,668,000 $773,491,000 $608,465,000 $536,311,000
Cash And Cash Equivalents $291,146,000 $457,469,000 $292,473,000 $337,544,000
Allowance For Doubtful Accounts Receivable - - $-200,000 $-200,000
Prepaid Assets - - - $48,967,000
Debt
Metric 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total Debt $75,538,000 $372,185,000 $379,435,000 $416,206,000
Long Term Debt And Capital Lease Obligation $69,372,000 $363,439,000 $366,557,000 $396,966,000
Current Debt And Capital Lease Obligation $6,166,000 $8,746,000 $12,878,000 $19,240,000
Long Term Debt - $287,730,000 $290,270,000 $292,804,000
Current Debt - $3,000,000 $3,000,000 $3,000,000
Other Current Borrowings - $3,000,000 $3,000,000 $3,000,000
Net Debt - - $797,000 -
Liabilities
Metric 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total Liabilities Net Minority Interest $590,590,000 $933,537,000 $920,225,000 $911,900,000
Total Non Current Liabilities Net Minority Interest $125,391,000 $413,317,000 $422,483,000 $440,614,000
Other Non Current Liabilities $56,019,000 $49,878,000 $42,384,000 $43,648,000
Current Liabilities $465,199,000 $520,220,000 $497,742,000 $471,286,000
Current Deferred Liabilities $1,249,000 $2,730,000 $6,816,000 $6,339,000
Payables And Accrued Expenses $386,824,000 $421,095,000 $393,119,000 $368,451,000
Payables $45,630,000 $65,649,000 $32,843,000 $55,721,000
Accounts Payable $45,630,000 $65,649,000 $32,843,000 $55,721,000
Liabilities Heldfor Sale Non Current - $0 $13,542,000 -
Other Current Liabilities - $4,542,000 $5,844,000 -
Non Current Deferred Liabilities - - - $11,491,000
Equity
Metric 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Common Stock Equity $1,464,977,000 $1,202,686,000 $1,043,753,000 $1,112,584,000
Total Equity Gross Minority Interest $1,464,977,000 $1,202,686,000 $1,043,753,000 $1,112,584,000
Stockholders Equity $1,464,977,000 $1,202,686,000 $1,043,753,000 $1,112,584,000
Gains Losses Not Affecting Retained Earnings $-1,967,000 $-3,110,000 $-10,889,000 $-3,723,000
Other Equity Adjustments $-1,967,000 $-3,110,000 $-10,889,000 $-3,723,000
Retained Earnings $-976,458,000 $-1,343,528,000 $-1,699,285,000 $-1,541,018,000
Other
Metric 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Treasury Shares Number $14,493,791 $5,589,218 $4,574,184 $3,853,222
Ordinary Shares Number $162,176,994 $166,979,833 $164,377,009 $161,937,327
Share Issued $176,670,785 $172,569,051 $168,951,193 $165,790,549
Tangible Book Value $1,381,060,000 $1,117,668,000 $923,046,000 $945,668,000
Invested Capital $1,464,977,000 $1,493,416,000 $1,337,023,000 $1,408,388,000
Working Capital $950,156,000 $965,286,000 $632,564,000 $590,883,000
Capital Lease Obligations $75,538,000 $81,455,000 $86,165,000 $120,402,000
Total Capitalization $1,464,977,000 $1,490,416,000 $1,334,023,000 $1,405,388,000
Treasury Stock $419,255,000 $189,336,000 $160,862,000 $142,658,000
Additional Paid In Capital $2,860,890,000 $2,736,934,000 $2,913,099,000 $2,798,325,000
Capital Stock $1,767,000 $1,726,000 $1,690,000 $1,658,000
Common Stock $1,767,000 $1,726,000 $1,690,000 $1,658,000
Preferred Stock $0 $0 $0 $0
Long Term Capital Lease Obligation $69,372,000 $75,709,000 $76,287,000 $104,162,000
Current Deferred Revenue $1,249,000 $2,730,000 $6,816,000 $6,339,000
Current Capital Lease Obligation $6,166,000 $5,746,000 $9,878,000 $16,240,000
Pensionand Other Post Retirement Benefit Plans Current $70,960,000 $83,107,000 $79,085,000 $77,256,000
Current Accrued Expenses $341,194,000 $355,446,000 $360,276,000 $312,730,000
Investments And Advances $73,148,000 $39,887,000 $131,610,000 $229,430,000
Held To Maturity Securities $73,148,000 $39,887,000 $131,610,000 $229,430,000
Goodwill $83,027,000 $83,027,000 $83,027,000 $92,873,000
Net PPE $311,809,000 $318,403,000 $320,458,000 $456,681,000
Accumulated Depreciation $-253,012,000 $-230,161,000 $-214,761,000 $-395,563,000
Gross PPE $564,821,000 $548,564,000 $535,219,000 $852,244,000
Leases $42,416,000 $39,893,000 $31,642,000 $52,526,000
Construction In Progress $58,391,000 $45,791,000 $78,017,000 $86,512,000
Other Properties $84,245,000 $91,460,000 $97,539,000 $115,627,000
Machinery Furniture Equipment $244,113,000 $237,728,000 $222,408,000 $398,099,000
Buildings And Improvements $134,699,000 $132,735,000 $104,666,000 $192,920,000
Land And Improvements $957,000 $957,000 $947,000 $6,560,000
Properties $0 $0 $0 $0
Finished Goods $30,877,000 $46,147,000 $44,126,000 $35,105,000
Work In Process $79,871,000 $68,843,000 $76,228,000 $59,105,000
Raw Materials $72,139,000 $71,416,000 $61,064,000 $56,125,000
Other Short Term Investments $460,522,000 $316,022,000 $315,992,000 $198,767,000
Non Current Deferred Revenue - - - $11,491,000
Fetched: 2026-02-02
Cash Flow Statement (Annual)
Free Cash Flow
Metric 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Free Cash Flow $405,640,000 $353,305,000 $-17,211,000 $72,695,000
Operating Activities
Metric 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Operating Cash Flow $439,124,000 $401,353,000 $21,044,000 $101,715,000
Cash Flow From Continuing Operating Activities $439,124,000 $401,353,000 $21,044,000 $101,715,000
Operating Gains Losses - - - $171,000
Investing Activities
Metric 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Capital Expenditure $-33,484,000 $-48,048,000 $-38,255,000 $-29,020,000
Investing Cash Flow $-111,308,000 $53,357,000 $-64,541,000 $-66,204,000
Cash Flow From Continuing Investing Activities $-111,308,000 $53,357,000 $-64,541,000 $-66,204,000
Net Other Investing Changes - - $1,273,000 $7,937,000
Financing Activities
Metric 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Repurchase Of Capital Stock $-200,282,000 $0 $0 -
Financing Cash Flow $-494,139,000 $-289,714,000 $-1,574,000 $29,072,000
Cash Flow From Continuing Financing Activities $-494,139,000 $-289,714,000 $-1,574,000 $29,072,000
Net Other Financing Charges $-29,637,000 $-303,474,000 $-18,204,000 $-16,571,000
Net Common Stock Issuance $-200,282,000 $0 $0 -
Other
Metric 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Repayment Of Debt $-291,792,000 $-3,000,000 $-3,000,000 $-3,243,000
Interest Paid Supplemental Data $23,010,000 $22,748,000 $13,563,000 $6,904,000
Income Tax Paid Supplemental Data $2,592,000 $44,243,000 $20,749,000 $1,888,000
End Cash Position $291,146,000 $457,469,000 $292,473,000 $337,544,000
Beginning Cash Position $457,469,000 $292,473,000 $337,544,000 $272,961,000
Changes In Cash $-166,323,000 $164,996,000 $-45,071,000 $64,583,000
Proceeds From Stock Option Exercised $27,572,000 $16,760,000 $19,630,000 $25,319,000
Common Stock Payments $-200,282,000 $0 $0 -
Net Issuance Payments Of Debt $-291,792,000 $-3,000,000 $-3,000,000 $20,324,000
Net Long Term Debt Issuance $-291,792,000 $-3,000,000 $-3,000,000 $20,324,000
Long Term Debt Payments $-291,792,000 $-3,000,000 $-3,000,000 $-3,243,000
Net Investment Purchase And Sale $-176,261,000 $101,051,000 $-28,044,000 $-45,408,000
Sale Of Investment $310,286,000 $355,522,000 $281,627,000 $295,010,000
Purchase Of Investment $-486,547,000 $-254,471,000 $-309,671,000 $-340,418,000
Net Business Purchase And Sale $97,976,000 $0 $1,758,000 $7,937,000
Sale Of Business $97,976,000 $0 $1,758,000 $7,937,000
Net PPE Purchase And Sale $-33,023,000 $-47,694,000 $-38,255,000 $-27,733,000
Sale Of PPE $461,000 $354,000 $0 $287,000
Purchase Of PPE $-33,484,000 $-48,048,000 $-38,255,000 $-28,020,000
Change In Working Capital $-98,150,000 $-36,663,000 $12,709,000 $-25,548,000
Change In Other Working Capital $-3,525,000 $-5,926,000 $-7,129,000 $12,259,000
Change In Other Current Liabilities $-1,693,000 $-6,813,000 $-20,499,000 $-21,110,000
Change In Other Current Assets $7,215,000 $15,387,000 $16,569,000 $17,051,000
Change In Payables And Accrued Expense $-49,156,000 $34,535,000 $30,433,000 $11,514,000
Change In Accrued Expense $8,811,000 $11,526,000 $14,899,000 -
Change In Payable $-57,967,000 $23,009,000 $15,534,000 -
Change In Account Payable $-57,967,000 $23,009,000 $15,534,000 -
Change In Prepaid Assets $2,254,000 $-34,847,000 $-5,328,000 $11,481,000
Change In Inventory $3,091,000 $-2,712,000 $-31,021,000 $-24,769,000
Change In Receivables $-56,336,000 $-36,287,000 $29,684,000 $-31,974,000
Changes In Account Receivables $-52,052,000 $-44,510,000 $25,250,000 $-38,011,000
Other Non Cash Items $4,512,000 $6,329,000 $27,281,000 $4,077,000
Stock Based Compensation $96,637,000 $100,905,000 $94,254,000 $87,622,000
Deferred Tax $40,522,000 $-99,902,000 $-32,795,000 $5,081,000
Deferred Income Tax $40,522,000 $-99,902,000 $-32,795,000 $5,081,000
Depreciation Amortization Depletion $28,533,000 $74,927,000 $77,862,000 $78,652,000
Depreciation And Amortization $28,533,000 $74,927,000 $77,862,000 $78,652,000
Net Income From Continuing Operations $367,070,000 $355,757,000 $-158,267,000 $-48,169,000
Issuance Of Debt - $0 $0 $23,567,000
Long Term Debt Issuance - $0 $0 $23,567,000
Net Intangibles Purchase And Sale - $0 $0 $-1,000,000
Purchase Of Intangibles - $0 $0 $-1,000,000
Purchase Of Business - - - $0
Asset Impairment Charge - - - $977,000
Fetched: 2026-02-02